Vaccine manufacturer – Curevac terminates production contracts – Economy

Curevac draws conclusions from the disappointing results of the study of its Covid-19 vaccine. The biotechnology company is giving up its first production partnerships for the manufacture of the vaccine. The contracts with Wacker Chemie and Celonic have been terminated, Curevac said. Other contracts remained in place. Curevac attributed this to lower demand for its vaccine, which only showed 48% efficacy in the crucial clinical trial. It is not known if the vaccine will ever be approved.

Related Articles

Back to top button